Navigation Links
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Date:6/8/2009

President, Global Head, Novartis Oncology Development. "These latest data show an antitumor effect in lymphoma that support the rationale for a Phase III study of Afinitor to prevent relapse in patients with diffuse large B-cell lymphoma, where there is a significant unmet medical need."

Novartis has initiated PILLAR-2 (PIvotaL Lymphoma triAls of RAD001), a Phase III trial investigating adjuvant treatment with everolimus (RAD001) in poor-risk patients with DLBCL who achieved complete remission with first-line rituximab combined with chemotherapy. This worldwide study will evaluate the potential of everolimus to extend disease-free survival in patients with DLBCL. The longer a patient with DLBCL is in remission the higher their likelihood to remain disease-free. There is no approved therapy for the approximately 50% of patients who will relapse after achieving a complete response on initial treatment, demonstrating an important unmet need(6).

EHA study details

The proof-of-concept, open-label, single-arm, multicenter Phase II study was designed to assess the efficacy and safety of everolimus in patients with relapsed/refractory aggressive or indolent NHL or Hodgkin's disease whose disease progressed despite prior treatment. Patients had received a median of four prior therapies (between one and 15 therapies). The study included patients with T-cell non-Hodgkin's lymphoma, Hodgkin's disease, follicular lymphoma, mantle cell lymphoma, DLBCL and small lymphocytic lymphoma; all of whom had experienced disease progression despite prior treatment. The primary endpoint of the study is to assess ORR. Secondary endpoints include assessment of progression-free survival (PFS), overall survival, time to disease progression and the safety profile of Afinitor(1).

In the trial, everolimus showed anticancer activity across multiple types of lymphoma, including T-cell non
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 According to a new market research ... Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, ... by MarketsandMarkets, the Medical Lifting Sling Market is poised to reach ... at a CAGR of 11.4 % from 2015 to 2020. ... rket data T ables and 65 ...
(Date:8/27/2015)... Women Grow , the fastest-growing professional networking organization for women ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... sessions. CWCBExpo in LA will take place September 16-18, 2015 ... in Los Angeles, CA , and is ... marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... LAKEWOOD, Ohio , Aug. 27, 2015  A ... according to Booz Allen Hamilton . A ... that product development inefficiencies are impeding and disrupting manufacturers, ... Can Cut Waste and Improve Value In Product Development ... cost of inaccessible data and how it affects the ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... , , , THOUSAND ... AMGN ) today announced that new data will be presented ... Prolia(TM) (denosumab) at the 2009 American Society for Bone and ... 2009. Prolia currently is being evaluated by regulatory bodies ...
... LEVADEX Analysis Shows Potential to ... Migraine is a common, debilitating ... United States, according to the,National Headache Foundation. Limitations of ... migraines, include slow onset of,significant pain relief between 45 ...
Cached Medicine Technology:Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 2Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 3Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 4Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 5Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 6Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 7Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 8MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS 2
(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... ... alcohol abuse, or those who might personally be struggling with chemical dependency, may ... post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... found an effective two-part treatment for microtears in the hamstring: ... with "dry-needling," in which repeated needle punctures cause controlled internal ... presented today at the annual meeting of the Radiological Society ... blood where it is needed at the site of a ...
... In the wake of multiple state bans on caffeinated ... to remove their products from the marketplace, an article published ... the scope of the public health problem and suggests areas ... manufacturers of caffeinated beer have withdrawn their products from the ...
... , ROCHESTER, Minn. - A team of Mayo Clinic researchers ... as apical ballooning syndrome (ABS), have blood vessels that don,t ... cause of this rare syndrome and may help with efforts ... so that appropriate therapies can be developed. The study is ...
... Through an innovative use of cell phone records, researchers at ... found that women appear to avoid contact with their fathers ... frequently on these high-fertility days and they hang up with ... Haselton, a UCLA associate professor of communication in whose lab ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... in children and teens over the last few decades, with ... youths, according to a new report. In one startling ... for Healthcare Research and Quality found that hospitalizations for eating ...
... HealthDay Reporter , MONDAY, Nov. 29 (HealthDay News) -- ... function for the "love hormone" oxytocin in human behavior. ... naturally occurring chemical, recalled intensified fond memories of their mothers ... men initially reported less close relationships with Mom, oxytocin seemed ...
Cached Medicine News:Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Caffeinated alcoholic beverages -- a growing public health problem 2Health News:Abnormal blood vessel function found in women with broken heart syndrome 2Health News:Contact with dads drops when women ovulate 2Health News:Contact with dads drops when women ovulate 3Health News:Contact with dads drops when women ovulate 4Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:'Love Hormone' Boosts Memories of Mom -- Good or Bad, Study Finds 2Health News:'Love Hormone' Boosts Memories of Mom -- Good or Bad, Study Finds 3
... The Raindrop® medication nebulizer achieves optimum lung ... particle size range is 1.04-1.10 µ at ... or air outlet., ,As the world ... healthcare providers the assurance of proven technology ...
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... World's smallest nebulizer utilizing Vibrating ... medications for patients suffering from Asthma, ... appreciate the small product size and ... transported wherever life takes them. Powerful ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: